Shares of Shire PLC (LON:SHP) traded down 0% during trading on Tuesday . The company traded as low as GBX 3,880.50 ($51.89) and last traded at GBX 3,880.50 ($51.89). 0 shares changed hands during trading, a decline of 100% from the average session volume of 2,570,000 shares. The stock had previously closed at GBX 3,880.50 ($51.89).
A number of analysts recently commented on the company. Shore Capital reiterated a “buy” rating on shares of Shire in a report on Wednesday, September 20th. Barclays restated an “equal weight” rating and issued a GBX 4,000 ($53.48) target price on shares of Shire in a research note on Monday, October 30th. Kepler Capital Markets restated a “buy” rating and issued a GBX 4,600 ($61.51) target price on shares of Shire in a research note on Wednesday, November 1st. Berenberg Bank lowered their target price on Shire from GBX 6,000 ($80.22) to GBX 5,900 ($78.89) and set a “buy” rating on the stock in a research note on Tuesday, October 24th. Finally, Liberum Capital restated a “buy” rating and issued a GBX 4,200 ($56.16) target price on shares of Shire in a research note on Monday, November 20th. Five investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of GBX 5,272.22 ($70.49).
The company has a market capitalization of $35,280.00 and a P/E ratio of 2,939.77.
ILLEGAL ACTIVITY NOTICE: This article was first published by Community Financial News and is the sole property of of Community Financial News. If you are viewing this article on another domain, it was illegally stolen and reposted in violation of international copyright laws. The original version of this article can be accessed at https://www.com-unik.info/2017/12/26/shire-shp-stock-price-down-0.html.
Shire Company Profile
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.